Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye DiseaseCollaboration Agreement • July 23rd, 2024
Contract Type FiledJuly 23rd, 2024FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that it has entered into a collaboration agreement with Senju Pharmaceutical Co., Ltd. (Senju), under which both companies intend to work to develop Senju’s corneal epithelial wound healing candidate, SJP-0035, for use with Eyenovia’s Optejet ® dispensing technology, as a potential treatment for chronic dry eye disease.